NCT07229586

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

A Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of SHR-7367 in Combination With Anti-tumor Agents in Subjects With Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	SHR-7367 Injection	SHR-7367 injection.
DRUG	SHR-1316 Injection	SHR-1316 injection.
DRUG	Paclitaxel for Injection	Paclitaxel for injection (Albumin Bound).
DRUG	Gemcitabine Hydrochloride for Injection	Gemcitabine Hydrochloride for injection.

Timeline

• Start date: 2025-12-02
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-11-17
• Last updated: 2025-12-19

Locations

1 site across 1 country: China